Risk assessment in localized primary cutaneous melanoma: A Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model

American Journal of Clinical Pathology

Volumn 118, Issue 4, 2002, Pages 504-511

  Tuthill, Ralph J ^a   Unger, Joseph M ^b   Liu, P Y ^b   Flaherty, Lawrence E ^c   Sondak, Vernon K ^d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Statistical Center   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cox regression; Cutaneous melanoma; Logistic regression; Risk assessment; Tumor infiltrating lymphocytes

Indexed keywords

ARTICLE; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; TUMOR ASSOCIATED LEUKOCYTE; ULCER; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SKIN TUMOR; STATISTICAL MODEL; SURVIVAL; SURVIVAL RATE; VALIDATION STUDY;

FEMALE; HUMANS; LOGISTIC MODELS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0036780666     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/WBF7-N8KH-71KT-RVQ9     Document Type: Article

References (29)

1. Clark WJ Jr, Elder DE, Guerry D IV, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893-1904.
2. Elder DE, Murphy GF. Melanocytic Tumors of the Skin. Bethesda, MD: Armed Forces Institute of Pathology/Universities Associated for Research and Education in Pathology; 1991:161-165.
3. Atlas of Tumor Pathobgy, Third series 3, Fascicle 2.
4. Wick MR. Prognostic factors for cutaneous melanoma. Am J Clin Pathol. 1998;110:713-718.
5. Rowley MJ, Cockerell CJ. Reliability of prognostic models in malignant melanoma. Am J Dermatopathol. 1991;13:431-437.
6. Pritchard ML, Woosley JT. Comparison of two prognostic models predicting survival in patients with malignant melanoma. Hum Pathol. 1995;26:1028-1031.
7. Szymik B, Woosley JT. Further validation of the prognostic model for stage I malignant melanoma based on tumor progression. J Cutan Pathol. 1993;20:50-53.
8. Balch CM, Soong S-J, Milton GW, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg. 1982;196:677-684.
9. Breslow A. Prognosis in cutaneous melanoma: tumor thickness as a guide to treatment. Pathol Annu. 1980;15:1-22.
10. Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000;88:1484-1491.
11. Vollmer RT. Malignant melanoma: a multivariate analysis of prognostic factors. Pathol Annu. 1989;24:383-407.
12. Braitman LE, Davidoff F. Predicting clinical states in individual patients. Ann Intern Med. 1996;125:406-412.
13. Wyatt JC, Altman DG. Commentary: prognostic models: clinically useful or quickly forgotten? BMJ. 1995;311:1539-1541.
14. Meyskens FL, Liu PY, Tuthill RJ, et al. Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group Study. J Clin Oncol. 1994;12:2060-2065.
15. Cox DR. Regression models and life-tables. J R Stat Soc. 1972;34(series B):187-220.
16. McDermott NC, Hayes DP, Al-Sader MH, et al. Identification of vertical growth phase in malignant melanoma: a study of interobserver agreement. Am J Clin Pathol. 1998;110:753-757.
17. Sahin S, Rao B, Kopf AW, et al. Predicting ten-year survival of patients with primary cutaneous melanoma: corroboration of a prognostic model. Cancer. 1997;80:1426-1431.
18. Aitchison TC, Sirel JM, Watt DC, et al. Prognostic trees to aid prognosis in patients with cutaneous malignant melanoma. BMJ. 1995;311:1536-1541.
19. MacKie RM, Aitchison T, Sirel JM, et al. Prognostic models for subgroups of melanoma patients from the Scottish melanoma group database 1979-86, and their subsequent validation. Br J Cancer. 1995;71:173-176.
20. Soong S-J, Shaw HM, Balch CM, et al. Predicting survival and recurrence in localized melanoma: a multivariate approach. World J Surg. 1992;16:191-195.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
22. Allen AC, Spitz S. Malignant melanomas, a clinicopathologic analysis of the criteria for diagnosis and prognosis. Cancer. 1953;6:1-45.
23. Cochran AJ. Histology and prognosis in malignant melanoma. J Pathol. 1968;97:459-468.
24. Clemente CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303-1310.
25. Busam KJ, Antonescu CR, Marghoob AA, et al. Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma: a study of interobserver agreement. Am J Clin Pathol. 2001;115:856-860.
26. Batch CM, Cascinelli N, Sim FH, et al. Elective lymph node dissection: results of prospective randomized surgical trials. In: Balch CM, Houghton AN, Sober AJ, et al, eds. Cutaneous Melanoma. 3rd ed. St Louis, MO: Quality Medical Publishing; 1998:209-226.
27. Schmoeckel C, Braun-Falco O. Prognostic index in malignant melanoma. Arch Dermatol. 1978;114:871-873.
28. Gershendwald JE, Thompson W, Mansfield PE, et al. Multiinstitutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I and II melanoma patients. J Clin Oncol. 1999;17:976-983.
29. Statius Muller MG, van Leeuwen PAM, de Lange-de Klerk ESM, et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with stage I or II cutaneous melanoma. Cancer. 2001;91:2401-2408.